NCT05183126 2026-03-06
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
University of Michigan Rogel Cancer Center
Phase 4 Recruiting
Clinical Trials
60 trialsNCT06519591 2026-02-18
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
Ruijin Hospital
Phase 2 Recruiting
NCT04209686 2025-12-03
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT06251973 2025-12-02
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04778839 2025-08-06
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
Phase 1 Recruiting
NCT04069273 2025-07-31
SEQUEL
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06490055 2025-07-18
Predicting the Efficacy in Advanced Gastric Cancer.
City of Hope Medical Center
Completed
NCT07045805 2025-07-01
Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT03044613 2025-03-06
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT06666582 2024-10-30
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
Hellenic Cooperative Oncology Group
Completed
NCT03760822 2024-07-08
SOCRATE
Federation Francophone de Cancerologie Digestive
Phase 2 Active not recruiting
NCT05395910 2024-05-29
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis
National University Hospital, Singapore
Phase 1 Recruiting
NCT06415669 2024-05-29
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT02931890 2024-05-02
CRITICS-II
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT05540145 2024-04-16
Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Completed
NCT03751761 2024-02-28
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Asan Medical Center
Phase 1/2 Completed
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed
NCT06222944 2024-01-25
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Peking University
Phase 2 Not yet recruiting
NCT03618758 2023-12-05
IPLUS
Seoul National University Bundang Hospital
Phase 1/2 Completed
NCT04308837 2023-11-14
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Phase 2 Unknown
NCT05400915 2023-11-13
Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients
Yonsei University
Phase 1/2 Completed
NCT01522768 2023-11-01
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05853172 2023-05-10
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03330028 2023-04-21
Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04047953 2023-04-05
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT05541146 2023-03-23
Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT02501603 2023-01-27
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Yonsei University
Phase 2 Completed
NCT05025033 2023-01-18
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05439993 2022-07-05
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Hallym University Medical Center
Phase 1/2 Recruiting
NCT04808466 2022-02-21
WUHIPEC01
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05228743 2022-02-08
Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT05111444 2021-11-08
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Fudan University
Phase 2 Unknown
NCT05095467 2021-10-27
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT02934464 2021-09-13
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 3 Unknown
NCT04943653 2021-07-06
IPXELOX
Seoul St. Mary's Hospital
Phase 1/2 Unknown
NCT04915807 2021-06-07
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Hallym University Medical Center
Unknown
NCT04888663 2021-05-21
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Phase 1/2 Unknown
NCT01183559 2021-01-22
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Fox Chase Cancer Center
Phase 1 Completed
NCT00020761 2020-08-03
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT04443036 2020-06-23
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
China Medical University, China
Phase NA Unknown
NCT00439608 2020-02-17
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Brown University
Phase 2 Completed
NCT01248403 2020-01-29
AIO-STO-0111
Krankenhaus Nordwest
Phase 3 Completed
NCT02406170 2019-10-22
REPEAT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT03263741 2019-07-08
Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer
Affiliated Hospital of Qinghai University
Phase 2 Unknown
NCT04001569 2019-06-28
AZD8186 and Paclitaxel in Advanced Gastric Cancer
Seoul National University Bundang Hospital
Phase 1/2 Unknown
NCT03990103 2019-06-19
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
China Medical University, China
Phase 2 Unknown
NCT03966118 2019-06-03
AIO-STO-0218
Charite University, Berlin, Germany
Phase 2 Unknown
NCT01283204 2019-01-29
Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer
Yonsei University
Phase 2 Completed